<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37527763</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-953X</ISSN><JournalIssue CitedMedium="Internet"><Volume>185</Volume><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Neurobiology of disease</Title><ISOAbbreviation>Neurobiol Dis</ISOAbbreviation></Journal><ArticleTitle>A panel of TDP-43-regulated splicing events verifies loss of TDP-43 function in amyotrophic lateral sclerosis brain tissue.</ArticleTitle><Pagination><StartPage>106245</StartPage><MedlinePgn>106245</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nbd.2023.106245</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0969-9961(23)00260-7</ELocationID><Abstract><AbstractText>TDP-43 dysfunction is a molecular hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). A major hypothesis of TDP-43 dysfunction in disease is the loss of normal nuclear function, resulting in impaired RNA regulation and the emergence of cryptic exons. Cryptic exons and differential exon usage are emerging as promising markers of lost TDP-43 function in addition to revealing biological pathways involved in neurodegeneration in ALS/FTD. In this brief report, we identified markers of TDP-43 loss of function by depleting TARDBP from post-mortem human brain pericytes, a manipulable in vitro primary human brain cell model, and identifying differential exon usage events with bulk RNA-sequencing analysis. We present these data in an interactive database (https://www.scotterlab.auckland.ac.nz/research-themes/tdp43-lof-db-v2/) together with seven other TDP-43-depletion datasets we meta-analysed previously, for user analysis of differential expression and splicing signatures. Differential exon usage events that were validated by qPCR were then compiled into a 'differential exon usage panel' with other well-established TDP-43 loss-of-function exon markers. This differential exon usage panel was investigated in ALS and control motor cortex tissue to verify whether, and to what extent, TDP-43 loss of function occurs in ALS. We find that profiles of TDP-43-regulated cryptic exons, changed exon usage and changed 3' UTR usage discriminate ALS brain tissue from controls, verifying that TDP-43 loss of function occurs in ALS. We propose that TDP-43-regulated splicing events that occur in brain tissue will have promise as predictors of disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Maize C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of Auckland, New Zealand; Centre for Brain Research, University of Auckland, New Zealand. Electronic address: m.cao@auckland.ac.nz.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Brigid</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Medical Imaging, University of Auckland, New Zealand; Centre for Brain Research, University of Auckland, New Zealand. Electronic address: b.ryan@auckland.ac.nz.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Medical Imaging, University of Auckland, New Zealand; Centre for Brain Research, University of Auckland, New Zealand. Electronic address: jane.wu@auckland.ac.nz.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curtis</LastName><ForeName>Maurice A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Medical Imaging, University of Auckland, New Zealand; Centre for Brain Research, University of Auckland, New Zealand. Electronic address: m.curtis@auckland.ac.nz.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faull</LastName><ForeName>Richard L M</ForeName><Initials>RLM</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Medical Imaging, University of Auckland, New Zealand; Centre for Brain Research, University of Auckland, New Zealand. Electronic address: rlm.faull@auckland.ac.nz.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dragunow</LastName><ForeName>Mike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of Auckland, New Zealand; Centre for Brain Research, University of Auckland, New Zealand. Electronic address: m.dragunow@auckland.ac.nz.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scotter</LastName><ForeName>Emma L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>School of Biological Sciences, University of Auckland, New Zealand; Centre for Brain Research, University of Auckland, New Zealand. Electronic address: emma.scotter@auckland.ac.nz.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Dis</MedlineTA><NlmUniqueID>9500169</NlmUniqueID><ISSNLinking>0969-9961</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="Y">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012326" MajorTopicYN="N">RNA Splicing</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Cryptic exon</Keyword><Keyword MajorTopicYN="N">Frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">Human brain</Keyword><Keyword MajorTopicYN="N">Splicing</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">mRNA</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>2</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>1</Day><Hour>19</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37527763</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2023.106245</ArticleId><ArticleId IdType="pii">S0969-9961(23)00260-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>